RUNX2 as a novel biomarker for early identification of patients progressing to advanced-stage mycosis fungoides
Interestingly, RUNX2, SHMT2, and MCM7 were upregulated in the enriched population of malignant T-cells in Pautrier's microabscesses in patients who later developed advanced stages of disease. Expression of RUNX2, SHMT2 and MCM7 in malignant T-cells was confirmed in a subset of patients in MF skin using scRNA-seq datasets across multiple studies and correlating with stage of disease. Taken together, we provide first evidence that RUNX2 has potential as a biomarker to identify MF patients progressing to advanced stage disease. As RUNX2 has not previously been linked to MF, our data also shows the analytical strength of combining spatial transcriptomics with scRNA-seq analysis.
Authors
- Niels Ødum (ORCID: https://orcid.org/0000-0003-3135-5624)
- Lise M. Lindahl (ORCID: https://orcid.org/0000-0003-3768-4146)
- Maria Danielsen (ORCID: https://orcid.org/0000-0002-8661-2256)
- Lars Iversen (ORCID: https://orcid.org/0000-0003-1816-4508)
- Morten Muhlig Nielsen (ORCID: https://orcid.org/0000-0002-8972-7577)
- Torben Steiniche (ORCID: https://orcid.org/0000-0001-5689-3555)
- Thomas Emmanuel (ORCID: https://orcid.org/0000-0003-3161-6409)
- Terkild B. Buus (ORCID: https://orcid.org/0000-0001-7180-6384)
- Claus Johansen (ORCID: https://orcid.org/0000-0002-5665-5212)
- Line Raaby (ORCID: https://orcid.org/0000-0002-3327-9613)
- Maria Gluud (ORCID: https://orcid.org/0000-0001-8877-3486)
- Rikke Bech (ORCID: https://orcid.org/0000-0001-7922-6317)
Institutions
- University of Copenhagen (DK)
- Aarhus University Hospital (DK)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.3389/fonc.2024.1421443
- Citations
- 3
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 1.60